Cargando…
Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes
Pulmonary hypertension (PH) is characterized by a resting mean pulmonary artery pressure (PAP) of 20 mmHg or more and is a disease of multiple etiologies. Of the various types of PH, pulmonary arterial hypertension (PAH) is characterized by elevated resistance in the pulmonary arterial tree. It is a...
Autores principales: | Beckmann, Taylor, Shelley, Patrisha, Patel, Darshan, Vorla, Mounica, Kalra, Dinesh K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609426/ https://www.ncbi.nlm.nih.gov/pubmed/36297354 http://dx.doi.org/10.3390/ph15101242 |
Ejemplares similares
-
New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023) -
Molecular Pathways in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2022) -
Myocarditis associated with COVID-19 and its vaccines - a systematic review
por: Rout, Amit, et al.
Publicado: (2022) -
Role of Lipid-Lowering Therapy in Peripheral Artery Disease
por: Belur, Agastya D., et al.
Publicado: (2022) -
A Rapidly Growing Cardiac Mass—Malignant or Benign?
por: Rout, Amit, et al.
Publicado: (2023)